AUTHORS
Tapan Kadia I, MD, Nathan Lee Roberts, MD2, Enrica Marchi, MD, PhD3, Ryotaro Nakamura, MD4, Christina Poh, MD5, Costas K Yannakou6, Yumeng Zhang, MD7, Lubomir Sokol, MD, PhD8, Clara Rolfs9, Mitul Gandhi, MD10, Jasmine Zain, M.D.11, Steven Horwitz, M.D.12, Mengyang Di, MD, PhD13, Tarsheen Sethi, MD14, Pier Luigi Zinzani, MD, PhD15, Lauren Shea, MD16, Cristina García Herce, MD17, Jake Shortt, MBBS, FRACP, FRCPA, PhD18, Lauren Pinter-Brown, MD19, Salvia Jain, MD20, Andrea Kantor21, Aimee Buc22, Jennifer Richardson, PhD23, Ruoshi Shi24, Alissa Keegan25, Wan-Jen Hong, M.D.26, Nenad Tomasevic, PhD27, Natali Pflug, MD28, Thierry Lamy, MD29, Marco Herling Sr30, Jonathan Brammer, MD31, Thomas P Loughran, MD32
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
3 Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 Epworth HealthCare, Melbourne, Victoria, Australia, University of Melbourne, Melbourne, Victoria, Australia
7 Moffitt Cancer Center, tampa, Florida, United States
8 Moffitt Cancer Center, tampa, Florida, United States
9 University of Leipzig, Leipzig, Germany
10 NEXT Oncology, Fairfax, Virginia, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Yale University School of Medicine, New Haven, Connecticut, United States
15 IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
16 University of Alabama, Birmingham, Birmingham, Alabama, United States
17 Hospital Universitari Vall d'Hebron, Barcelona, Spain
18 Monash Health, Clayton, Victoria, Australia
19 University of California, Irvine, Irvine, California, United States
20 Massachusetts General Hospital, Boston, Massachusetts, United States
21 Dren Bio, San Carlos, California, United States
22 Dren Bio, San Carlos, California, United States
23 Dren Bio, San Carlos, California, United States
24 Dren Bio, San Carlos, California, United States
25 Dren Bio, San Carlos, California, United States
26 Dren Bio, San Carlos, California, United States
27 Dren Bio, San Carlos, California, United States
28 University of Cologne, Cologne, Germany
29 Pontchaillou University Hospital, Rennes, France
30 University of Leipzig, Leipzig, Germany
31 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
32 University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
ABSTRACT
Large granular lymphocytic leukemia (LGLL) is a chronic, incurable lymphoproliferative disorder of cytotoxic CD8+ T cells or natural killer (NK) cells. LGLL is associated with neutropenia, recurrent infections, and transfusion-dependent or symptomatic anemia. No approved therapies exist, and while available options, mainly immunosuppressants, are modestly effective, patients are subject to the long-term effects of chronic immunosuppression. Dibotatug (DR-01), a non-fucosylated human IgG antibody targeting CD94, which is expressed on NK cells, γδ T cells, and αβ terminal effector CD8+ T cells, leads to their depletion by antibody-dependent cellular cytotoxicity and is a potential new targeted therapy for patients with LGLL.
A Phase 1/2 open-label study (NCT05475925) assessing dibotatug safety, efficacy, and pharmacodynamics, enrolled relapsed/refractory (R/R) and treatment-naïve (TN) LGLL patients and R/R cytotoxic lymphoma patients. Eligible patients received intravenous dibotatug (0.3–10 mg/kg) using one of three induction regimens during Cycle 1, followed by monthly dosing during dose escalation. Dose optimization evaluated the Selected Induction Regimen at either 1 or 6 mg/kg on days C1D1/D8/D15 followed by monthly dosing. Efficacy in LGLL patients was assessed using modified ECOG 5998 response criteria (Loughran 2015).
As of May 2026, 101 LGLL patients (95 [94%] T cell LGLL; 6 [6%] NK cell LGLL) were enrolled; 11 (11%) were TN and 90 (89%) were R/R, 58 (57%) were male, and the median age was 66 years (range, 24–87). ECOG performance status was: 0 (43%), 1 (50%), or 2 (7%) at study entry, and all patients must have required treatment for LGLL. Primary indications for treatment were severe neutropenia (42 [42%]), transfusion-dependent anemia (33 [33%]), symptomatic anemia (17 [17%]), and neutropenia with recurrent infections (9 [9%]). Median number of prior lines of therapy was 2 (range, 1–13). Prior therapies for R/R patients include methotrexate (n=74 [84%]), cyclophosphamide (43 [49%]), cyclosporine (43 [49%]), ruxolitinib (13 [15%]), and alemtuzumab (8 [9%]). 73/101 (73%) patients across all dose levels remain on study treatment.The most frequent treatment-related adverse events were infusion-related reactions (IRR; n=17 [17%]); the majority were grade 1–2 and occurred with the first dose. No IRR led to dose reduction or discontinuation except in the first patient before IRR prophylaxis was optimized. There were no treatment-related deaths or dose-limiting toxicities across all dose levels tested.
Preliminary efficacy focused on the 78 patients who received 1 or 6 mg/kg at the Selected Induction Regimen, including 67 R/R and 11 TN. At the protocol-specified response assessment at C4D1, there were 45 R/R and 1 TN patients evaluable for response. 32 patients, including 10 who were TN, continue on study and have not yet reached the C4D1 assessment. The overall response rate (ORR) was 26/45 (58%) in R/R and 1/1 (100%) in TN patient. In R/R patients, there were 17 [38%] complete responses [CR], 9 [20%] partial responses [PR] and 19/45 [42%] stable disease (SD); 1 (100%) TN patient had a CR. Time to first response ranged from 0.9-5.5 months. 9/27 (33%) responders reached first response by C2D1 (one month of treatment). CRs were observed in both T-LGLL 15/43 (35%) and NK-LGLL in 3/3 (100%) patients and in patients whose primary indications for treatment were neutropenia and anemia. 22/27 (81%) responders and 11/19 (57%) of SD patients remain on study treatment. The median duration of response (DoR) has not been reached; the longest DoR is currently 27+ months and ongoing in a patient with CR.
Patients who achieved CR or PR exhibited rapid and sustained improvements in absolute neutrophil counts and hemoglobin levels regardless of their primary indication of treatment. Patients with CR showed early and sustained depletion of LGL counts and reduced levels of serum granzyme B, a cytotoxic marker.
Additional preliminary safety and efficacy data continues to show that dibotatug is well-tolerated. Response rates are promising with early and durable responses that support continued development of dibotatug as a novel therapy for LGLL.
DISCLOSURES
Tapan Kadia I, MD: Astellas - Honoraria; Sobi - Honoraria; Sumitomo - Honoraria; Kura - Honoraria; Abbvie - Honoraria; Genentech - Honoraria; Sellas - Honoraria; DrenBio - Honoraria; Syndax - Honoraria; Regeneron - Research Funding; Sellas - Research Funding; Pfizer - Research Funding; DrenBio - Research Funding; Daichii - Research Funding; Jazz - Research Funding; Taiho - Research Funding; BMS - Research Funding; Abbvie - Research Funding; Genentech - Research Funding; Ascentage - Research Funding; DrenBio - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Tempus - Consultancy (Includes expert testimony)